by Aleksandar Nikolajevic | Aug 27, 2026 | Newsletter
August 2026 Newsletter Summary: New antibody approved: Clesrovimab (Enflonsia®) received EU approval in April 2026 — the third prophylactic RSV antibody after Palivizumab and Nirsevimab. Weight-independent dosing: Fixed 105 mg dose for all newborns and infants, unlike...
by Aleksandar Nikolajevic | Aug 5, 2026 | Institute
Institute of Virology Innsbruck Joins the Global Virus Network as Austria’s First Center of Excellence The Institute of Virology at the Medical University of Innsbruck has been accepted into the Global Virus Network (GVN) as a Center of Excellence. It is the...
